Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Analysts at Jefferies have previously said that iptacopan could hit $3.6 billion in peak annual sales if it gets approved for all its target indications, which along with PNH include atypical ...

Dr Weitz discusses the studies on iptacopan, pegcetacoplan, and danicopan presented at ASH 2024, highlighting their effectiveness in treating PNH. Iptacopan demonstrated significant improvements ...

The APPLY-PNH and APPOINT-PNH studies demonstrated that iptacopan significantly improved quality of life and global health status for PNH patients, with notable improvements in cognitive ...